2000 - 2001 Publications & Presentations by members of our department.

Publications
by members of CSU-Pharmaceutical Sciences

Presentations
by members of CSU-Pharmaceutical Sciences

1999 - 2000

  1. Zed PJ, Marra F, Stiver GH, Devonshire V, Jewesson PJ.  Continuous intrathecal pump infusion of baclofen with antibiotic drugs for treatment of pump-associated meningitis:  Case  report.  J Neurosurg 2000;92:347-349.

  2. Gill NJ, Frighetto L, Marra CA, Jewesson PJ.  Patient perceptions of substituting a reference-based drug while in hospital:  Focus on H2-receptor antagonists.  Can J Hosp Pharm 2000;53:86-91.

  3. Stiver G, Wai AO, Chase L, Frighetto L, Marra C, Jewesson P.  Outpatient intravenous antibiotic therapy:  The Vancouver Hospital experience.  Can J Infect Dis 2000;11 (Suppl A):11a-14a.

  4. Shalansky K, Sunderji R.  A simple warfarin dosing nomogram for orthopedic prophylaxis.  Can J Hosp Pharm 2000;53:40-44.

  5. Zed PJ.  Low Molecular Weight Heparins and Coronary Artery Disease.  Current Cardiology Reports 2000;2:61-68.

  6. Marra F.  Azithromycin Working Group.  Chlamydia trachomatis and Azithromycin. Reviews in Contemporary Pharmacotherapy 2000;11:139-256.  (F. Marra was involved in working on the section involving screening for Chlamydia trachomatis and health economic aspects of azithromycin treatment).

  7. Frighetto L, Marra CA, Bryce EA, Stiver HG, Jewesson PJ.  Economic impact of a Standardized Orders for Antimicrobial Prophylaxis (S.O.A.P.) Program.  Ann Pharmacother 1999;34:154-160.

  8. de Lemos Jane M., Carr Roxane R., Shalansky Karen F., Bevan David R., Ronco Juan J.  Paralysis in the critically ill:  Intermittent pancuronium bolus compared with continuous infusion.  Crit Care Med 1999;27:2648-2655.

  9. Esmail Z, Sunderji R, Gin K.  Amiodarone-induced pulmonary toxicity.  Pharmacother 1999;19:1463-1466.

  10. Zed PJ, Tisdale JE, Borzak S.  Low-molecular-weight heparin in acute coronary syndromes.  Arch Intern Med 1999;159:1849-1857. 

  11. Zed PJ.  Low-molecular weight heparin should replace unfractionated heparin in the management of acute coronary syndromes.  J Thromb Thrombolysis 1999;8:79-87. 

  12. Sunderji R, Campbell L, Shalansky KF, Fung A, Carter C, Gin K.  Outpatient self management of warfarin therapy: a pilot study.  Pharmacother 1999;19:787-793.

  13. Loewen P, Marra C, Marra F.  Influence of the methods of reporting clinical trial data on pharmacists’ willingness to recommend drug therapy. Can J Hosp Pharm 1999;52:145-149.

  14. Schwagly N, Frighetto L, MacDougall C, Jewesson PJ.  Experience with ceftazidime parenteral-to-parenteral dosage stepdown in the empiric treatment of febrile neutropenia.  Pharmacother 1999;19:641-647.

  15. Olson K, Marra F, Sunderji R.  The role of Chlamydia pneumoniae in the pathogenesis of coronary heart disease.  J Pharm Tech 1999;15:157-161.

  16. Marra F, Yoshida EM.  Treatment of chronic hepatitis C virus infection with "-Interferon alone or in combination with ribavirin.  Infect Dis in Clin Pract 1999;8:429-438.

  17. Yoshida EM, Erb SR, Partovi N, Scudamore CH, Chung SW, Frighetto L, Eggen HJ, Steinbrecher UP.  Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin.  Liver Transpl Surg 1999;5:520-525.

  18. Warkentin D, Ippoliti C, Bruton J, van Besein K, and Champlin R.  Toxicity of single daily dose gentamicin in stem cell transplantation.  Bone Marrow Transplant 1999;23:57-62.

  19. Sunderji R, Shalansky KF, Beauchesne MF, Fung A.  Is there a role for nifedipine in hypertensive urgencies?  Can J Hosp Pharm 1999;52:167-170.

  20. Slavik RS, Rhoney DH.  Indomethacin: A review of its cerebral blood flow effects and potential use for controlling intracranial pressure in traumatic brain injury patients.  Neurological Research 1999;21:491-499.

  21. Sauder C, Porterfield P, Shalansky KF, Tong KL.  Subcutaneous administration of loxapine.  Amer J of Health-System Pharm 1999;56:1259-1261.

  22. Balen RM, Marra CA, Zed PJ, Cohen M, Frighetto L.  Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: a Canadian hospital perspective.  Pharmacoecon 1999;16:533-542.

  23. Yoshida EM, Partovi N, Ross PL, Landsberg DN, Shapiro JR, Chung SW.  Racial differences between solid organ transplant donors and recipients in British Columbia.  Transplantation 1999;67:1324-1329.

  24. Frighetto L, Loewen PS, Dolman J, Marra CA.  Cost-effectiveness of prophylactic dolasetron or droperidol vs rescue therapy in the prevention of (PONV) in ambulatory gynecologic surgery.  Can J Anesth 1999;46:536-543.

  25. Zed PJ, Krenzelok EP.  Management of acetaminophen overdose.  Am J Health-Syst Pharm 1999;56:1081-1093.

  26. Low A.  5-ASA - Non-interchangeable.  The Tablet - a publication of the BC Pharmacy Association 1999;8:9.  (Non-refereed)

  27. Low A, Miller RA, Pang PY, Singh AK.  Comparative disintegration and dissolution testing of three formulations of 5-aminosalicylic acid (5-ASA).  (Abstract published in Gastroenterol 1999;116(Part 2):A89 (Abstract G0326)).  (Non-refereed)

  28. Sunderji R, Campbell L, Shalansky K, Fung A, Carter C, Gin K.  Outpatient self-management of warfarin therapy:  A pilot study.  Can J Hosp Pharm 1999;54:54(Abstract).4.  Low A.  Ropinirole (Requip®) associated with decreased risk of dyskinesia when used in early Parkinson’s disease.  B.C. Parkinson’s Disease Association, Viewpoints, Newsletter 1999 September:4,8.  (Non-refereed)

  29. Zed PJ.  Spotlight on Dr. Peter Zed.  BC Pharmacy 1999;June:27-29.  (Non-refereed)

  30. Sunderji R, Esmail Z, Gin K.  Pulmonary effect of low dose amiodarone:  A review of the risk and recommendations for surveillance.  Can J Cardiol 2000 (refereed, in press).

  31. Loewen PS, Marra CA, Zed PJ. 5-HT3  receptor antagonists versus traditional agents for the prophylaxis of postoperative nausea and vomiting: a meta-analysis. Can J Anesthesiol 2000 (referred, in press).

  32. Abu-Laban RB, Zed PJ, Purssell RA, Evans K. Topical benzocaine-induced methemoglobinemia: case report and systematic review of the literature. Can J Emerg Med 2000 (refereed, in press).

  33. de Lemos JM, Tweeddale MG, Chittock DR.  The Vancouver Interaction and Calmness Scale:  A valid reliable and responsive scale to measure quality of sedation in the critically ill.  J Clin Epidemiol 2000 (refereed, in press).

  34. Shepherd JD, Warkentin DI, Haser L.  Bladder.  In Ratain (ed.) Outline of Oncology therapeutics.  W.B. Saunders Co., Philadelphia, PA.  (refereed, in press, book chapter).

1998 - 99

  1. Marra F, Frighetto L, Marra C, Sleigh K, Stiver G, Bryce E, Reynolds R, Jewesson P. Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for treatment of serious infections: a Canadian hospital perspective. Ann Pharmacother 1999;33:156-162.

  2. Warkentin, D. Antiemetic guidelines: Vancouver Hospital and Health Sciences Centre. J Oncol Pharm Practice 1999;4:191-192.

  3. Loewen P, Marra CA, Marra F. Systematic review of the treatment of early lyme disease. Drugs 1999;57:157-173.

  4. Zed P, Loewen P, Robinson RG. Medication-induced headache: diagnosis and treatment. Ann Pharmactother 1999;33:61-72.

  5. Slavik RS, Rybak MJ, Lerner SA. Trimethoprim/sulfamethoxazole-induced tremor in a patient with AIDS. Ann Pharmacother 1998;32:189-192.

  6. Esmail ZN, Loewen PS. Losartan as an alternative to ACE inhibitors in patients with renal dysfunction. Ann Pharmacother 1998;32:1096-1098.

  7. Marra F, Reynolds R, Stiver G, Bryce E, Sleigh K, Frighetto L, MacDougall C, Jewesson P. Piperacillin/tazobactam vs. imipenem: A double-blind, randomized formulary feasibility study at a major teaching hospital. Diag Microbiol Infect Dis 1998;30:355-368.

  8. Wai A, Lo A, Ayman A, Marra F. Vancomycin-induced acute interstitial nephritis. Ann Pharmacother 1998;32:1160-1164.

  9. Zed P, Frighetto L, Sunderji R, Marra C. Cost-effectiveness analysis of abciximab: A Canadian hospital perspective. Ann Pharmacother 1998;32:536-542.

  10. Frighetto L, Marra C, Gerber P, MacDougall C, Dolman J, Jewesson P. Addition of sevoflurane to the formulary: Impact on a surgical daycare unit. Can J Hosp Pharm 1998;51:169-175.

  11. Marra F. Treatment of hepatitis C. Hosp Pharm Practice 1998;5:1-10.

  12. Frighetto L, Marra CA, Stiver HG, Bryce Elizabeth A, Jewesson PJ. Effect and economic impact of a "Standardized Orders for Antimicrobial Prophylaxis" (SOAP) Program. APUA Newsletter 1998;16:1,5-6.

  13. Frighetto L, Marra C, Gerber P, MacDougall C, Dolman J, Jewesson P. Addition of sevoflurane to the formulary: Impact on a surgical daycare unit. Can J Hosp Pharm 1998;51:169-74.

  14. Loewen P, Sunderji R, Gin K. The efficacy and safety of combination warfarin and aspirin therapy: A systematic review of the available literature and update of current guidelines. Can J Cardiol 1998;14:717-726.

  15. de Lemos J, Ronco J. Does "Train of four" monitoring reduce recovery time after Neuromuscular Blockade? Crit Care Med 1998;26:1920. (Letter).

  16. de Lemos JM, Tweeddale MG, Weglo K, Foster DA, Biggs S, Plumstead B, Chittock DR. The Vancouver Sedation Scale: A valid, reliable and responsive tool for measuring sedation in the critically ill. Intensive Care Med 1998;21:485.

  17. Low A. The 5-ASA dilemma. The Inside Tract (Published by the Northwestern Society of Intestinal Research) 1998:3-5.

  18. de Lemos JM, Carr RR, Shalansky KF, Bevan DR, Ronco JJ. Paralysis in the critically ill: pancuronium bolus vs. continuous infusion. Crit Care Med (refereed, in press).

  19. Zed PJ, Krenzelok EP. Management of acetaminophen overdose. Am J Health Syst Pharm. 1999 Jun 1;56(11):1081-91

  20. Zed PJ, Tisdale JE, Borzak S. Low-molecular-weight heparin in acute coronary syndromes. Arch Intern Med. 1999 Sep 13;159(16):1849-57.

  21. Zed PJ. Low-molecular weight heparin should replace unfractionated heparin in the management of acute coronary syndromes. J Thromb Thrombolysis. 1999 Aug;8(2):79-87

  22. Sunderji R, Campbell L, Shalansky K, Fung A, Carter C, Gin K. Outpatient self-management of warfarin therapy: a pilot study. Pharmacother 1999 (refereed, in press).

  23. Loewen P, Marra C, Marra F. Influence of presentation of clinical trial data on pharmacists’ willingness to recommend drug therapy. Can J Hosp Pharm 1999 (refereed, in press).

  24. Lambert N, MacDougall C, Frighetto L, Jewesson PJ. Experience with ceftazidime IV-IV dosage stepdown in the empiric treatment of febrile neutropenia: A first report. Pharmacother 1998 (refereed, in press).

  25. Slavik RS, Rhoney DH. Indomethacin: A review of its cerebral blood flow effects and potential use for controlling intracranial pressure in traumatic brain injury patients. Neurol Res. 1999 Jul;21(5):491-9.

  26. Olson K, Marra F, Sunderji R. The role of Chlamydia pneumoniae in the pathogenesis of coronary heart disease. J Pharm Tech 1999 (refereed, accepted).

  27. Beauchesne MF, Sunderji R, Shalansky KF, Fung A. Is there a role for nifedipine in hypertensive urgencies? Can J Hosp Pharm 1999 (refereed, accepted).

  28. Sauder C, Porterfield P, Shalansky KF, Tong KL. Subcutaneous loxapine: a new route of administration. Am J Health Syst Pharm. 1999 Jun 15;56(12):1259-61.

  29. Warkentin D, Ippoliti C, Bruton J, van Besein K, and Champlin R. Toxicity of single daily dose gentamicin in stem cell transplantation. Bone Marrow Transplant. 1999 Jul;24(1):57-61.

1997-98

  1. Elbe D, Frighetto L, Nickoloff D, Jewesson P. Use of cefixime in an IV to oral stepdown program to reduce antimicrobial costs. Formul 1998;33:54-63. 

  2. Marra CA, Patrick DB, Reynolds R, Marra F. Chlamydia Trachomatis in adults and adolescents: Clinical and economic considerations. Pharmacoecon 1998;13:191-222. 

  3. Partovi N, Carr R, Yoshida M, Chung S. Primary induction with mycophenolate mofetil and corticosteroids in a liver transplant recipient with hepatorenal syndrome. Ann Pharmacother 1998;32:45-8. 

  4. Sunstrum C, Carruthers-Czyzemski P, Michalko K, Thompson R, Carruthers S, Larochelle P, Pollak T, Jewesson P, McLean W. The difficulty in assessing the relative therapeutic merit of new antineoplastic drugs. Can J Clin Pharmacol 1997;4:118-125. 

  5. Hughes C, Sunderji R, Gin K. Oral Propafenone for rapid conversion of recent onset atrial fibrillation. Can J Cardiol 1997;13:839-42. 

  6. Jewesson PJ, Chow A, Wai A, Frighetto L et al. A double-blind, randomized study of three antimicrobial regimens in the prevention of infections after elective colorectal surgery. Diag Microbiol Infect Dis 1997;29:155-65.

  7. Frighetto L, Marra C, Jewesson P. Tracking and reporting drug expenditures. Amer J Health-Syst Pharm 1997;54:2303-2306. 

  8. Sunderji R, Press N, Amin H, Gin K. Unstable angina associated with sertraline: A case report. Can J Cardiol 1997;13:849-51. 

  9. Ferreira E, Sunderji R, Gin K. Is sotalol effective in converting atrial fibrillation to sinus rhythm? Pharmacother 1997;17:1233-7. 

  10. Loewen P. Use of E-mail for conducting surveys. Amer J Health-Syst Pharm 1997;54:1334. 

  11. Letwin S, Loewen P, Marra F. PharmaNet database and seamless care. Can J Hosp Pharm 1997;50:160. 

  12. Marra F, Marra CA, Patrick DB. Cost-effectiveness analysis of azithromycin and doxycycline for Chlamydia cervicitis: A Canadian perspective. Can J Infect Dis 1997;8:202-8. 

  13. Marra F, Jewesson PJ. A Comparison of piperacillin/tazobactam versus imipenem: Formulary Considerations. J Infect Diseases Pharmacother 1997;2:55-80. 

  14. Wrishko RE, Levine M, Primmett D, Kim S, Partovi N, Lewis S, Landsberg D, Keown P. Investigation of a possible interaction between ciprofloxacin and cyclosporine in renal transplant patients. Transplantation 1997;64:996-99. 

  15. Ippoliti C, Morgan A, Warkentin D, Whimbey E, van Besein K, Mehra R, Khouri I, Giralt S, Gajewski J, Deisseroth A, Champlin R, Andersson B, Przepiorka P. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir. Bone Marrow Transplant 1997;20:491-495. 

  16. Gajewski J, Gjertson D, Cecka M, Tonai, Przepiorka D, Hunt L, Giralt S, Chang KW, Feig S, Territo M, Andersson B, van Besien K, Khouri I, Fischer H, Babbitt L, Ippolitti C, Schiller G, Lill M, Warkentin D, Neumann J, Petz L, Terasaki P, Champlin R. The impact of T-cell depletion on the effects of HLA DR beta 1 and DZ beta allele matching in HLA serologically identical unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant 1997;3:76-82. 

  17. Wai A, Lo A, Ayman A, Marra F. Vancomycin-induced acute interstitial nephritis. Ann Pharmacother (accepted - February 1998). 

  18. Zed P, Frighetto L, Sunderji R, Marra C. Cost-effectiveness analysis of abciximab: A Canadian hospital perspective. Ann Pharmacother. 1998 May;32(5):536-42.

  19. Marra F, Reynolds R, Stiver G, Bryce E, Sleigh K, Frighetto L, MacDougall C, Jewesson P. Piperacillin/tazobactam vs. imipenem: A double-blind, randomized formulary feasibility study at a major teaching hospital. Diag Microbiol Infect Dis (accepted - December 1997). 

  20. Low A. Case Studies in Inflammatory Bowel Disease for Pharmacists. Continuing education booklet for pharmacists. March 1998. (non-refereed)

  21. Low A. The Role of 5-ASA in Inflammatory Bowel Disease. Continuing education Slide Presentation Kit. February 1998. (non-refereed)

  22. Loewen P, Marra C. Internet resources of interest to pharmacists. British Columbia Pharmacy Journal 1997;6:30-33. (non-refereed)

  23. Loewen P, McCormack J. Treatment of Acute Migraine Headaches. Therapeutics Initiative Therapeutics Letter 1997 (November/December):22a-23b. (non-refereed)

  24. Low A. The 5-ASA dilemma. BC Pharmacy Asssociation 1997(Dec):23-24. (non-refereed)

  25. Wai A. On the Home Team. BC Pharmacy Association 1997(Dec):20-21.

  26. Frighetto L, Marra C, Gerber P, MacDougall C, Doleman J, Jewesson P.  Addition of sevoflurane to the formulary:  Impact on a surgical daycare unit.  Can J Hosp Pharm 1998;51(4):169-173

  27. Jewesson P.  Overcoming antibiotic resistance: A physician's guide.  Can J CME 1998;137.

1996 - 97

  1. Marra F, Partovi N, Jewesson PJ. Aminoglycoside administration as a single daily dose: an improvement to current practice or a repeat of previous errors? Drugs. 1996 Sep;52(3):344-70.

  2. Committee on Antimicrobial Agents (Jewesson P, member), Fong IW. Management of diabetic foot infection: a position paper. Can J Infect Dis 1996;7:361-365. 

  3. Committee on Antimicrobial Agents (Jewesson P, member), Laverdiere M. Itraconazole: an oral systemic antifungal triazole: a position paper. Can J Infect Dis 1996;7:366-369. 

  4. Herar S, Jewesson P. Pharmaceutical Industry Representative Activities at a Major Teaching Hospital. Can J Hosp Pharm 1996;49:256-260. 

  5. Low A, Sunderji R. Calcium channel blockers. BC Pharmacy. December 1996:18-21. (non-refereed)

  6. Warkentin D. The Clinical Application of Hematopoietic Growth Factors in Blood and Bone Marrow Transplantation. Frontiers 1996;7:1-4. (non-refereed)

  7. White R, Friedrich L, Burgess D, Warkentin D, Bosso J. Comparative in-vitro pharmacodynamics of imipenem and meropenem against P. aeruginosa. Antimicrob Agents Chemother 1996;40:904-8. 

  8. Ng T, Shalansky KF, Ustad T. Understanding Psychiatric medication: A multi-component patient education system. Can J Hosp Pharm 1996;49:80-4. 

  9. Marra CA, Shalansky KF. Ampicillin-induced maculopapular veruse urticarial rash. Ann Pharmacotherapy 1996;30:401-2. 

  10. Marra CA. Useful sites for pharmacists. Pharm Practice 1996;12:12-17. (non-refereed)

  11. Elbe D, Frighetto L, Nickoloff D, Jewesson P. A survey of prescriber perceptions and practice of IV-PO stepdown anti-infective therapy. Can J Hosp Pharm 1996;49:244-251. 

  12. Lun E, Frighetto L, MacDougall C, and Jewesson PJ. Computer-assisted retrospective clinical activities statistics (CARCAS): three years of experience. Can J Hosp Pharm 1996;49:146-50. 

  13. Malfair S, Frighetto L, Nickoloff D, Martinusen S et al. Evaluation of the use of cefuroxime and cefuroxime axetil in an intravenous-oral stepdown program. Ann Pharmacother 1996;30:337-42. 

  14. Marra CA, Carleton BC, Lynd LD, Marra F, McDougal AR, Chow D, McKerrow R. Drug and poison information on the internet: part 2, identification and evaluation. Pharmacother 1996;16:806-818. 

  15. Marra F, Partovi N, Jewesson PJ. Aminoglycoside administration as a single daily dose: an improvement to current practice or a repeat of previous errors? Drugs 1996;52:344-370. 

  16. Marra F, Cairns B, Jewesson PJ. Vancomycin serum concentration monitoring: the middle ground is best. Clin Drug Invest 1996;12:105-118. 

  17. Traboulay SJ, Fitzgerald JM, Shalansky KF, Sunderji R, O’Malley B et al. Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation. Pharmacother 1996;16:1076:84. 

  18. Trottier LR, Wing DS. Eye care products in non-prescription drug reference for health professionals, Ottawa: Canadian Pharmaceutical Association, pp. 163-222, 1996. (non-refereed)

  19. Yoshida E, Shackleton CR, Erb S, Scudamore C, Mori LM, Eggen H, Wynn V, Partovi N, Keown P. Late Acute Rejection Occurring in Liver Allograft recipients. Can J Gastroenterol 1996;10:376-80. 

Pre-April 1996 (Selected publications)

  1. McCormack J and Jewesson P. "A critical re-evaluation of the therapeutic range of aminoglycosides." Reviews of Infectious Diseases, 14:320-339 (1992).

  2. Martinusen S, Chen D, Frighetto L, Bunz D, Stiver G and Jewesson P. "A comparison of cefoxitin and ceftizoxime in a hospital therapeutic interchange program." Canadian Medical Association Journal; 148:1161-1169 (1993). (Recipient of 1990 B.C. Residency Project Award/Upjohn and CSHP National Residency Project Award 1990)/Organon.

  3. Reesor C, Mamdani F, Baker A and Jewesson P. "Development and implementation of empiric aminoglycoside dosing guidelines." Pharmacotherapy; 13:408-414 (1993).

  4. Rayani S, Reesor Nimmo C, Frighetto L, Martinusen S, Nickoloff D, Reece D and Jewesson P. "Implementation and evaluation of a standardized HSV prophylaxis protocol on a leukemia/bone marrow transplant unit." Annals of Pharmacotherapy; 28:852-6 (1994).

  5. Jewesson P. "Cost-Effectiveness and Value of an IV Switch." PharmacoEconomics; 5(Suppl.2):20-26 (1994).

  6. Leong W and Jewesson P. "A Retrospective Evaluation of Imipenem Use in Bone Marrow Transplant Patients." Clinical Therapeutics: The International Journal of Drug Therapy; 16:752-766 (1994).

  7. Shalansky KF and Shalansky SJ. Selection and monitoring of muscle relaxants during mechanical ventilation. Can J Hosp Pharm 1992;45:47-52.

  8. Shalansky KF, Vaughan LM, Ustad T, Tweeddale MG, Sahn S. Absolute bioavailability of aminophylline liquid administered enterally in adults requiring mechanical ventilation. Clin Pharm 1992;11:428-32.

  9. Htan E, Shalansky KF, Mouat B. What is the appropriate dose of metered-dose inhaler (MDI) for mechanically ventilated patients? Ann Pharmacotherapy 1992;26:1247-8.

  10. Shalansky KF, Htan EYH, Lyster DM, Mouat B and Tweeddale MG. In vitro evaluation of the effect of metered-dose inhaler administration technique on aerosolized drug delivery. Pharmacotherapy 1993;13:233-8.

  11. Shalansky KF, Reesor-Nimmo C. Drug therapy for disease states: Asthma. In: How to Use Drugs! A Practical and Clinical Guide to Drug Use. McCormack J, Brown G, Levine M, Ruedy J, Rangno R (eds). Philadelphia: W.B.Saunders, Inc., 1994 (in press)

  12. Sauder CL, Shalansky KF, Hewko RA. Transdermal scopolamine and transient psychosis. Can J Hosp Pharm 1994;47:67-9.

  13. Cocco LC, Jager KI, Shalansky KF, Sunderji R, Tweeddale MG. Assessment of ipratropium and salbutamol in ventilated patients without obstructive airways disease. Can J Respir Ther 1995;31:23-8.

  14. Shalansky KF, Macready J. Risk of seizures with ciprofloxacin. Can J Hosp Pharm 1995;48:370-2.

  15. Marra CA, Shalansky KF. What are the differences between ampicillin rashes? Ann Pharmacother 1996;30:401-2.

  16. Ng T, Shalansky KF, Ustad R. Understanding psychiatric medications - development of a multi-component patient education program. Can J Hosp Pharm 1996;49:80-4.

  17. Cocco L, Jager KL, Shalansky KF, Tweedale MG.  Efficacy of ipatropium bromide in combination with salbutamol in the treatment of mechanically ventilated patients without obstructive airway disease.  Can J Respir Ther 1995;31:23-8.

  18. Low A, Sunderji R.  The calcium channel blocker controversy:  how will you respond to your client?  BC Pharmacy 1996 (in press)

  19. Friedrich LV, White RL, Burgess DS, Warkentin DI, and Bosso JA. Comparative stability of imipenem and meropenem in mueller-hinton broth at room temperature, during incubation, and during frozen storage. J Infect Dis Pharmacotherapy 1995;1,No 2:21-34.

  20. Gajewski JL, Mehra R, Warkentin DI, and Champlin RE. Outpatient autologous bone marrow transplantation. Cancer Bull 1995;47:298-300.

  21. Ajani JA, Dodd LG, Daugherty K, Warkentin D, and Ilson DH. Taxol-induced soft-tissue injury secondary to extravasation: characterized by histopathology and clinical course. JNCI 1994;86, No 1:51-53.

  22. Yoshida EM, Shackleton CR, Erb SR, Scudamore CH, Mori LM, Ford J, Eggen H, Wynn V, Partovi N, Keown PA.  Late acute rejection occurring in liver allograft recipients.  Canadian Journal of Gastroenterology (in press).

  23. Partovi N, Malmberg C, Shalansky KF, Fagan M, Roscoe DL, Ostrow DN, Fradet G.  Evaluation of antibacterial prophylaxis in lung and heart-lung transplant patients in prevention of early post-operative infection.  Journal of Heart and Lung Transplantation. (in press)

  24. Marra F, Partovi N, Jewesson P.  Single daily dosing of aminoglycosides: an improvement to current practice or a repeat of previous errors?  Drugs 1996;52(3):344-370.

  25. Partovi N, Chan W, Nimmo CR.  Evaluation of a patient education program for solid organ transplant patients.  Can J Hosp Pharm  1995;48:72-8.

  26. Morton WA, Laird LK, Crane DF, Partovi N, Frye LH.  A prediction model for identifying alcohol withdrawal seizures.  Am J Drug Alcohol Abuse 1994;20:75-86.

  27. Marra F, Jewesson PJ. High level aminoglycoside resistant enterococci: an emerging nosocomial pathogen.  Hosp Pharm Management 1995;1(3):3-4.

  28. Marra CA, Carleton BC, Lynd LD, Marra F, McDougal AR, Chow D, McKerrow R.  Drug and Poison information resources on the internet: Part 2, identification and evaluation.  (accepted in Pharmacotherapy)

  29. Marra F, Partovi N, Jewesson PJ.  Single daily dosing of aminoglycosides: an improvement to current practice or a repeat of previous errors?  (Drugs 1996;52(3);344-369)

  30. Carleton BC, Marra CA,Wu MJ, McInnes D, Brown L. The pediatric health-related clinical research index: a PHaRCRI from previous attempts at finding quality-of-life information in pediatric patients. Journal of Pediatric Pharmacy Practice 1996;1:86-93.

  31. Marra CA, Levine M, McKerrow R, Carleton BC. Overview of health-related quality-of-life in pediatric patients: Application to pharmacotherapeutic and pharmacoeconomic outcomes. Pharmacotherapy 1996;16:879-888.

  32. Marra CA, Carleton BC, Lynd LD, Marra F, McDougal A, Chow D, McKerrow R. Drug and poison information resources on the Internet: Part 2, identification and evaluation Pharmacotherapy 1996; 16:806-18.

  33. Marra CA. Minocycline for rheumatoid arthritis. Canadian Pharmaceutical Journal 1996;September:21-23.

  34. Marra CA. Pharmacy and the Internet. Pharmacy Practice 1996;12: 12-17.

  35. Marra CA, Lynd LD, McKerrow R, Carleton BC. Drug and poison information resources on the Internet: Part 1, an introduction. Pharmacotherapy 1996;16:537-46.

  36. Marra CA, Shalansky KF. Ampicillin-induced maculopapular versus urticarial rash. Annals of Pharmacotherapy 1996;30:401-2.

  37. Marra CA, Nimmo CR, Jewesson PJ. A prospective survey of knowledge and perceptions of ondansetron: What do health care workers know about this drug? Canadian Journal of Hospital Pharmacy 1995;48:336-42.

  38. Lun E, Frighetto L, MacDougall C, and Jewesson PJ. Computer-assisted retrospective clinical activities statistics (CARCAS): three years of experience. Can J Hosp Pharm 1996; 49:146-50.

  39. Malfair S, Frighetto L, Nickoloff D, Martinusen S et al. Evaluation of the use of cefuroxime and cefuroxime axetil in an intravenous-oral stepdown program. Ann Pharmacother 1996; 30:337-42.

  40. Jewesson PJ, Stiver G, Wai A, Frighetto L et al. Double-blind comparison of cefazolin and ceftizoxime for prophylaxis against infections following elective biliary tract surgery. Antimicrobial Agents and Chemotherapy, 1996; 40:70-4.

  41. Scudamore CH, Randall TE, Jewesson PJ, Shackleton CR, Salvian AJ, Fagan M, Frighetto L et al. Aprotinin reduces the need for blood products during liver transplantation. The American Journal of Surgery 1995; 169:546-549.

  42. Frighetto L, Nickoloff D, and Jewesson PJ. Antibiotic therapeutic interchange program: six years of experience. Hospital Formul 1995; 30:92-105.

  43. Frighetto L, Martinusen SM, Mamdani F, and Jewsesson PJ. Ciprofloxacin use under a reserved drug and stepdown promotion program. Can J Hosp Pharm 1995; 48:35-42.

  44. Rayani SA, Reesor Nimmo CJ, Frighetto L, Martinusen SM et al. Implementation and evaluation of a standardized herpes simplex virus prophylaxis protocol on a leukemia/bone marrow transpant unit. Ann Pharmacother 1994; 28:852-6.

  45. Martinusen S, Chen D, Frighetto L, Bunz D, et al. A comparison of cefoxitin and ceftizoxime in a hospital therapeutic interchange program. Can Med Assoc J 1993; 148:1161-9.

  46. Frighetto L, Nickoloff D, Martinusen S, Mamdani F et al. IV-PO Stepdown Program: Four years experience in a large teaching hospital. DICP Ann Pharmacother 1992; 26:1447-51.

  47. Gutensohn A, Bunz D, Frighetto L, Jewesson P. Outcome of a ceftriaxone/cefotaxime interchange programme in a major teaching hospital. Chemotherapy 1991; 37 (Suppl 3):15-21.

  48. Frighetto L, Bunz D, Jewesson P. Prescriber identification program. Can J Hosp Pharm 1990; 44:35-6.

  49. Bunz D, Frighetto L, Gupta S, Jewesson P. Simple ways to promote cost containment. DICP Ann Pharmacother 1990; 24:546.

1999 - 2000

External Podium Presentations

  1. Slavik R.  “Selected topics in critical care:  tried, tested, and true”.  2000 Canadian Society of Hospital Pharmacists Banff Conference, Banff, Alberta, March 2000.

  2. Zed PJ. “Advances in Antisecretory Therapy for Acute Upper Gastrointestinal Bleeding Peptic Ulcers”. Pharmacology Rounds, Royal Columbian Hospital, New Westminster, B.C., March, 2000.

  3. Zed PJ. “Dyspepsia Management in the Palm of Your Hand”. Canadian Society of Hospital Pharmacists, Banff Seminar, Banff Conference Centre, Banff, Alberta, March, 2000.

  4. Partovi N.  “Developing limiting sampling strategy for cyclosporine area-under-the-curve monitoring in lung transplant recipients”.  Annual Meeting of Canadian Society of Transplantation, Mont Tremblant, Quebec, March 2000.

  5. Partovi N.  “Does long-term mycophenolate mofetil therapy affect allograft re-infection in liver transplant recipients with hepatitis C?  Canadian Digestive Disease Conference.  Quebec City, Quebec, March 2000.

  6. Low A.  “Transfer of Information via PharmaNet Study (TIPS)”.  Seamless Care Forum.  Annual C.S.H.P. Western Branches Banff Seminar, Banff, Alberta, March 2000.

  7. Loewen P.  “Understanding the role of COX-2 inhibitors in osteoarthritis and rheumatoid arthritis”.  Merck Frosst CPE Event (Community Pharmacists), Richmond, B.C., March 2000.

  8. Loewen P.  “ACE-Inhibitors in CHF:  How much is enough?”.  11th Annual Drug Therapy Decision Making Course, Richmond, B.C., March 2000.

  9. Loewen P.  “Antiplatelet therapies for secondary prevention:  When is another rose not a stinker?”.  11th Annual Drug Therapy Decision Making Course, Richmond, B.C., March 2000.

  10. Loewen P.  “Postoperative Nausea & Vomiting: the Big Little Problem”. Canadian Society of Hospital Pharmacists Western Branches Banff Seminar, March 2000.

  11. Zed PJ. “Proton Pump Inhibitors in Hospitalized Patients”. Canadian Society of Hospital Pharmacists 31st Professional Practice Conference, Westin Harbour Castle, Toronto, Ontario, February 2000.

  12. Jewesson P.  “Economic Impact of Standardized Orders for Antimicrobial Prophylaxis (S.O.A.P.) Program”. Canadian Society of Hospital Pharmacists 31st Professional Practice Conference, Westin Harbour Castle, Toronto, Ontario, February 2000 (National Research Award Presentation).

  13. Jewesson P.  “A Novel Ciprofloxacin Stepdown Program in the Treatment of High-risk Febrile Neutropenia:  A Clinical and Economic Analysis”. Canadian Society of Hospital Pharmacists 31st Professional Practice Conference, Westin Harbour Castle, Toronto, Ontario, February 2000 (National Research Award Presentation).

  14. Jewesson P.  “Hospital Formularies:  A Left-over from the Past?”.  9th Annual Invitation Management and Clinical Seminar for Pharmacy Managers.  Harrison Conference 2000.  Harrison Hot Springs, B.C., February 2000.

  15. Zed PJ. “Infections in Emergency Medicine”. Round Table Discussion Leader, Canadian Society of Hospital Pharmacists 31st Professional Practice Conference, Westin Harbour Castle, Toronto, Ontario, February 2000.

  16. Zed PJ. “Innovative Pharmacy Practice in Emergency Medicine”. Canadian Society of Hospital Pharmacists 31st Professional Practice Conference, Westin Harbour Castle, Toronto, Ontario, February 2000.

  17. Slavik R.  “Management of agitation in the neurology/neuro-ICU patient”.  Canadian Association of Neurosciences Nurses (CANN) Meeting, Vancouver, B.C., February 2000.

  18. Low A.  “Parkinson's Disease - Review of Therapy and New Developments (Insights into Continuity of Care)”.  9th Annual Invitation Management and Clinical Seminar for Pharmacy Managers, Harrison Conference 2000, Harrison Hot Springs, B.C., February, 2000. 

  19. Partovi N.  “Role of new anti-rejection medications in prevention & treatment of rejection in solid organ transplantation”.  Transplant Rounds, British Columbia Transplant Society, Vancouver, B.C., January 2000.

  20. Partovi N.  “New treatment in the management of pulmonary hypertension”.  Canadian Society of Hospital Pharmacists 31st Professional Practice Conference, Westin Harbour Castle, Toronto, Ontario, January 2000.

  21. Low A.  “Medication Therapy in Parkinson's Disease”.  B.C. Parkinson's Disease Association, Education Meeting, Vancouver, B.C., January, 2000.

  22. Low A.  “Transfer of Information via PharmaNet Study (TIPS)”.  Seamless Care Forum.  The Annual C.S.H.P. Western Branches Banff Seminar, Banff, Alberta, March, 2000.

  23. Marra F.  “Pharmacokinetics of Ambisome”.  Fungal Update: Focus on Liposomal Amphotericin.  Fugisawa CME (Hematology/Infectious Diseases), Key Largo, Florida, January 2000.

  24. Slavik R.  “Applied pharmacokinetics and pharmacodynamics in the critically-ill”.  Critical Care Academic Day, Medical ICU Teaching Module, St. Paul’s Hospital, Vancouver, B.C., December 1999.

  25. Loewen P. “Osteoarthritis:  Symptom Management & The Role of the Pharmacist”.  The University of Alberta/Alberta Continuing Pharmacy Education, Calgary, Edmonton, Lethbridge, and Red Deer, December 1999.

  26. Marra F.  “Influenza: Nothing to Sneeze At”.  London Drugs Annual Education Event for Pharmacists.  London Drugs Headquarters, Richmond, B.C., November 1999.

  27. Slavik R.  “Managing your hypercholesterolemia”.  Medicine Centre Pharmacies Patient Education Lecture Series, Plaza 500 Hotel, Vancouver, B.C., November 1999.

  28. Partovi N.  “The role of oral ganciclovir in prevention of CMV disease in Solid Organ Transplant patients”.  Transplant Rounds, British Columbia Transplant Society, Vancouver, B.C., November 1999.

  29. Low A, Dodge D.  “Creating Patient Partnerships: Optimizing Patient Outcomes Using Migraine Management Plans”, The Division of Continuing Pharmacy Education, Faculty of Pharmaceutical Sciences, UBC Merck Frosst Seminars, Terrace, Kelowna, Surrey, Vancouver and Victoria, British Columbia, October 1999.

  30. Wai AO, Frighetto L, Marra CA, Chan E, Jewesson PJ.  “A cost analysis of an outpatient parenteral antibiotic program (OPAT):  A Canadian teaching hospital and Ministry of Health Perspective”.  Infectious Diseases Society of America 37th Annual Meeting, Philadelphia, Pennsylvania, October 1999.

  31. Zed PJ. “Glycoprotein IIb/IIIa Receptor Antagonists: Pharmacotherapy for Acute Coronary Syndromes in the New Millennium” Pharmacology Grand Rounds, Surrey Memorial Hospital, Surrey, B.C., October 1999.

  32. Low A.  “Medication Therapy in Parkinson’s”.  B.C. Parkinson’s Disease Association Kootenay Regional Conference, Trail, B.C., October 1999.

  33. Low A.  “Parkinson’s Disease”.  Simon Fraser University – Downtown Campus, Gerontology Course, Vancouver, B.C., October 1999.

  34. Low A.  “Parkinson’s Disease:  The Theory and The Therapy”.  The October Pharmacy AM Breakfast Meeting of the B.C. Pharmacy Association, Vancouver, B.C., October 1999.

  35. Loewen P. “Developing an Institutional Approach to Managing Postoperative Nausea and Vomiting”.  (Teleconference to 14 B.C. hospitals).  Registered Nurses Association of British Columbia, October 1999.

  36. Loewen P.  “Current topics in Diabetes, Hypertension, Hormone Replacement therapy, and Osteoarthritis”.  Grand Rounds, Kelowna General Hospital, Family Practitioners, Vernon.  The Therapeutics Initiative, Penticton, October 1999.

  37. Zed PJ. “Acute Coronary Syndromes: Pharmacotherapy in the New MIllenium” Guest Lecturer, Pharmacy Seminar, Faculty of Pharmacy, Memorial University of Newfoundland, St. John’s NF, September 1999.

  38. Zed PJ. “Acute Management of Gastrointestinal Bleeding Peptic Ulcers” Canadian Society of Clinical Pharmacists – Newfoundland Branch, Clinical Symposium, Hotel Newfoundland, St. John’s NF, September 1999.

  39. Low A.  “Seamless Care Forum – Perspectives from a Tertiary Care Teaching Hospital”.  Canadian Society of Hospital Pharmacists (B.C. Branch) Clinical Symposium, Vancouver, B.C., September 1999. 

  40. Low A.  “Hard Facts for Soft Bones – Osteoporosis and the role of the Pharmacist”.  Saskatchewan Pharmacy Association, Continuing Pharmacy  Education, Regina and Saskatoon, Saskatchewan, September 1999.

  41. Loewen P.  “Postoperative Nausea and Vomiting: The Big Little Problem”.  Canadian Society of Hospital Pharmacists (B.C. Branch) Clinical Skills Symposium, Vancouver, B.C., September 1999.

  42. Zed PJ. “Antisecretory Therapy for Acute GI Bleeding: Are Proton Pump Inhibitors the Answer?”. Canadian Society of Hospital Pharmacists – B.C. Branch, Fraser Valley Chapter, Northview Golf & Country Club, Surrey, B.C., August 1999.

  43. Loewen P.  “Clopidogrel for prevention of cardiovascular events: Defining its place in therapy”.  Canadian Society of Hospital Pharmacists (B.C. Branch) Fraser Valley Chapter, Continuing Education Event, Surrey, B.C., August 1999.

  44. Shalansky K.  “Renal dysfunction and dialysis”.  UBC Pharmacy Continuing Education, University of British Columbia, Vancouver, B.C., June, 1999.

  45. Low A.  “The impact of neurological drugs on function”.  Neurological Centre, Lunch and Learn, Vancouver, B.C., June 1999.

  46. Low A.  “What are you doing for your diabetic patient”.  Canadian College of Clinical Pharmacy (CCCP) and Associated faculties of Pharmacy of Canada (AFPC) Joint Meeting, Quebec City, Quebec, June 1999.

  47. Zed PJ. “Antisecretory Therapy for Acute GI Bleeding: Are Proton Pump Inhibitors the Answer?”. Canadian Society of Hospital Pharmacists (B.C. Branch) Okanagan Spring Update, Eldorado Hotel, Kelowna, B.C., May 1999.

  48. Loewen P.  “Clopidogrel:  Ticlopidine’s nemesis?”  Canadian Society of Hospital Pharmacists (B.C. Branch) Okanagan Spring Update, Kelowna, B.C., May 1999.

  49. Low A.  “Pharmacist’s role in managing Parkinson’s Disease”.  BC’s Long Term Care Pharmacy Conference – New Ideas for Old Friends, Burnaby, B.C., May 1999.

  50. Low A.  “Parkinson’s disease – The Patient’s Perspective”.  BC’s Long Term Care Pharmacy Conference – New Ideas for Old Friends, Burnaby, B.C., May 1999.

  51. Marra F.  “The new fluoroquinolones: the differences and similarities”. Canadian Society of Hospital Pharmacists (B.C. Branch) Spring Therapeutics Update, Vancouver, B.C., April 1999.

 Internal Presentations

  1. Runikis A.  “Drugs commonly used in Psychiatry”.  Clinical Clerks/MSI.  Vancouver Hospital & Health Sciences Centre, UBCH Site, (repeated at 8 sessions).

  2. Runikis A, Low A.  “Schizophrenia Pharmacologic Treatment Algorithm”.  Active and Associate Medical Staff, Department of Psychiatry.  Vancouver Hospital & Health Sciences Centre, VGH Site, (repeated at 2 sessions).

  3. Shalansky K.  “Vancomycin and high flux dialysis”.  Pharmacists (Infectious Diseases Rounds) and Neurologists.  Vancouver Hospital & Health Sciences Centre, VGH Site, (repeated at 3 sessions).

  4. Shalansky K.  “Bedside kinetics”.  Pharmacists.  Vancouver Hospital & Health Sciences Centre, VGH Site, (repeated at 3 sessions).

  5. Slavik R.  “Antimicrobial therapy in the ICU:  Principles and practical applications”.  Critical Care Medical Resident Teaching Series, Vancouver Hospital & Health Sciences Centre, VGH Site, (repeated at 4 sessions).

  6. Slavik R.  “Clinical application of intropes and vasopressors in the ICU”.  Critical Care Medical Resident Teaching Series, Vancouver Hospital & Health Sciences Centre, VGH Site, (repeated at 3 sessions).

  7. Zed PJ. “Enoxaparin the Management of Unstable Angina and Non-Q-Wave Myocardial Infarction” Nursing Education Conference, Department of Emergency Medicine, Vancouver Hospital & Health Sciences Centre, VGH Site, (repeated at 2 sessions).

  8. Zed PJ, “Antispychotics” Emergency Department Nursing Orientation. Vancouver Hospital & Health Sciences Center, VGH Site, (repeated at 2 sessions).

  9. Zed PJ. “The Use of Psychotropic Drugs in the Emergency Department: Managing the Aggressive Psychiatric Patient” Emergency Department Education Days, Vancouver Hospital & Health Sciences Center, VGH Site, (repeated at 2 sessions).

  10. Zed PJ. “Low-Molecular Weight Heparin for the Outpatient Treatment of Deep Vein Thrombosis: The VGH Program”. Emergency Department Education Days, Vancouver Hospital & Health Sciences Center, VGH Site, (repeated at 2 sessions).

  11. Loewen P.  “Managing postoperative nausea and vomiting on the surgical ward”.  Nurses, Nursing Education & Support Services, Vancouver Hospital & Health Sciences Centre, UBCH Site, March 2000.

  12. Slavik R.  “Management of shock states:  focus on inotropes and vasopressors”.  Trauma Special Care Unit Nursing Training Module, Vancouver Hospital & Health Sciences Centre, VGH Site, March 2000.

  13. Zed, PJ. “Low Molecular Weight Heparin in Acute Coronary Syndromes: An Evidence-Based Approach”. Academic Rounds, Department of Emergency Medicine, Vancouver Hospital & Health Sciences Centre, VGH Site, March 2000.

  14. Marra F.  “The impact of bacterial resistance on the treatment of community-acquired pneumonia”. Emergency Department Pharmacology Rounds, Vancouver Hospital & Health Sciences Centre, VGH Site, March  2000.

  15. Zed, PJ. “Therapeutic Controversies in the Management of Acute Upper Gastrointestinal Bleeding”  Pharmacology Rounds, Department of Emergency Medicine, Vancouver Hospital & Health Sciences Centre, VGH Site, February 2000.

  16. Partovi N.  “Review of anti-rejection medications for solid organ transplant”.  Education Day for SOT unit.  Vancouver Hospital & Health Sciences Centre, VGH Site, February 2000.

  17. Jewesson P.  “How to effectively dissect a clinical drug trial publication and have fun doing it”.  Research Education Series, Research Affairs, Vancouver Hospital & Health Sciences Centre, VGH Site, February 2000.

  18. Slavik R.  “Pharmacological management of atrial fibrillation”.  CSU Pharmaceutical Sciences Rounds, Vancouver Hospital & Health Sciences Centre, VGH  Site, January 2000.

  19. Marra F. “Case studies in HIV/AIDS”.  Vancouver Hospital and Health Sciences Centre UBCH Site Clinical Teaching Unit Grand Rounds, Vancouver, B.C., January 2000.

  20. Zed, PJ. “Acute Coronary Syndromes: Past, Present and Future” Pharmacology Rounds, Department of Emergency Medicine, Vancouver Hospital & Health Sciences Centre, VGH Site, December 1999.

  21. Zed, PJ. “Thrombolysis in the Emergency Department” Emergency Department Nursing Orientation. Vancouver Hospital & Health Sciences Center, VGH Site, December 1999.

  22. Zed, PJ. “Acute Pain Management and Conscious Sedation” Emergency Department Nursing Orientation. Vancouver Hospital & Health Sciences Center, VGH Site, December 1999.

  23. Zed, PJ. “Rapid Sequence Intubation” Emergency Department Nursing Orientation. Vancouver Hospital & Health Sciences Center, VGH Site, December 1999.

  24. Slavik R.  “Bugs/drugs and management of agitation in the critically-ill patient”.  Critical Care Nursing Training Module, Vancouver Hospital & Health Sciences Centre, VGH Site, December 1999.

  25. Slavik R.  “Acute pharmacologic management of atrial fibrillation:  evidence…what evidence”.  Emergency Medicine Pharmacology Rounds, Vancouver Hospital & Health Sciences Centre, VGH Site, November 1999.

  26. Loewen P.  “Postoperative nausea and vomiting:  The Big Little problem”.  Nurses, Nursing Education Day, Vancouver Hospital & Health Sciences Centre, UBCH Site, November 1999.

  27. Loewen P.  “Drug therapy for acute migraine headache”.  Emergency Department Pharmacology Rounds, Vancouver Hospital & Health Sciences Centre, UBCH Site, October 1999.

  28. Loewen P.  “Enoxaparin for acute coronary syndromes”.  Emergency Department physicians, Vancouver Hospital & Health Sciences Centre, UBCH Site, October 1999.

  29. Loewen P.  “Antiplatelet therapies for prevention of cardiovascular events:  The role of clopidogrel”.  Pharmacists.  Vancouver Hospital & Health Sciences Centre, UBCH Site, October 1999.

  30. Marra F.  “A cost-effectiveness analysis of pneumococcal vaccination for street-involved, HIV infected patients”.  Academic Rounds, Division of Infectious Diseases, Vancouver Hospital & Health Sciences Centre, Vancouver, B.C, October 1999.

  31. Jewesson P.  “Bugs and Drugs”.  Emergency Department Pharmacology Rounds.  The University of British Columbia Division of Emergency Medicine, Vancouver Hospital & Health Sciences Centre, Vancouver, B.C., September 1999.

  32. Marra F.  “Two cases of mucormycosis”. Vancouver Hospital and Health Sciences Centre Infectious Diseases Intracity Rounds, Vancouver, B.C., September 1999.

  33. Slavik R.  “Pharmacological management of traumatic brain injury with basilar skull fracture:  Case example”.  CSU Pharmaceutical Sciences Rounds Case Presentation, Vancouver Hospital & Health Sciences Centre, VGH Site, June 1999.

  34. Marra F.  “The new fluoroquinolones: the differences and similarities”.  Vancouver Hospital & Health Sciences Centre Infectious Diseases Seminar, Vancouver Hospital & Health Sciences Centre, VGH Site, June 1999.

  35. Slavik R.  Critique of Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, et al.  Stress doses of hydrocortisone reverse hyperdynamic septic shock:  A prospective, randomized, double-blind, single-centre study.  Crit Care Med 1999;27:723-732.  CSU Pharmaceutical Sciences Journal Club, Vancouver Hospital & Health Sciences Centre, VGH Site, June 1999.

  36. Shalansky K.  “Carnitine study results”.  Nephrologists.  Vancouver Hospital & Health Sciences Centre, VGH Site, June 1999.

  37. Zed PJ. “Low-Molecular Weight Heparin for the Outpatient Treatment of Deep Vein Thrombosis”. Emergency Department Academic Rounds, Vancouver Hospital & Health Sciences Center, VGH Site, May 1999.

  38. Runikis A.  “Mechanisms, Side Effects and Interactions of Psychoactive Drugs”.  Changeways Group, Vancouver Hospital & Health Sciences Centre, UBCH Site, April 1999.

  39. Warkentin D.  “Adenoviral infections in recipients of stem cell transplantation”.  Bone Marrow Transplantation Seminar, Vancouver Hospital & Health Sciences Centre, VGH Site, April 1999.

1998 - 99

External Podium Presentations

  1. Marra F. "The newer fluoroquinolones". Canadian Society of Hospital Pharmacists (B.C. Branch) Spring Drugs Update, Vancouver, B.C., April, 1999.

  2. Partovi N, Yoshida E, Ross P, Landsberg D, Shapiro RJ, Chung S. "Racial differences between Solid Organ Transplant donors and recipients in British Columbia: A retrospective analysis 1992-97". Canadian Society of Transplantation & Canadian Association of Transplantation. Annual Scientific Meeting, Chateau Lake Louise, Lake Louise, Alberta, March 1999.

  3. Marra CA. "The Internet as a Source of Drug and Poison Information. Information Networks and the Public Domain". Drug Information Association 11th Annual Euromeeting. Netherlands Congress Centre, The Hague, Netherlands, March 1999.

  4. Partovi N. "Post-transplant lymphoproliferative disease (PTLD) following lung transplantation in Canadian transplant centers". Canadian Transplant Society Annual Meeting, Chateau Lake Louise, Lake Louise, Alberta, March 1999.

  5. Partovi N. "Liver Transplantation for chronic Hepatitis B infection with the use of combination lamivudine and low dose Hepatitis B Immunoglobulin". Canadian Transplant Society Annual Meeting, Chateau Lake Louise, Lake Louise, Alberta, March 1999.

  6. Marra F. "Bacterial resistance to antimicrobial agents: clinical concerns?". Canadian Society of Hospital Pharmacists 25th Annual Banff Seminar, Banff, Alberta, March 1999.

  7. Slavik R. "Acute Cardioversion of Atrial Fibrillation: Evidence...What Evidence?". Canadian Society of Hospital Pharmacists 25th Annual Banff Seminar, Banff, Alberta, March 1999.

  8. Loewen P. "An evidence-based approach to treatment of acute migraine headache". 10th Annual Drug Therapy Decision Making Course, Richmond, B.C., March 1999.

  9. Loewen P. "Cost-effectiveness of prophylactic dolasetron or droperidol vs. Rescue therapy in the prevention of post-operative nausea and vomiting (PONV) in ambulatory gynecology patients". Canadian Society of Hospital Pharmacists 30th Professional Practice Conference, Westin Harbour Castle, Toronto, Ontario, February 1999.

  10. Loewen P. "Homocysteine: Cholesterol for the next millennium?". British Columbia Community Hospital Pharmacy Directors Association Meeting, Harrison Hot Springs, B.C., February 1999.

  11. Shalansky K. "Management of Cachexia". Canadian Society of Hospital Pharmacists 30th Professional Practice Conference, Westin Harbour Castle, Toronto, Ontario, February 1999.

  12. Sunderji R. "Outpatient Self-Management of Warfarin Therapy: A Pilot Study". Canadian Society of Hospital Pharmacists 30th Professional Practice Conference, Westin Harbour Castle, Toronto, Ontario, February 1999.

  13. Slavik R. "Antimicrobial Pharmacodynamics: Principles and Practical Applications". Canadian Society of Hospital Pharmacists 30th Professional Practice Conference, Westin Harbour Castle, Toronto, Ontario, February 1999.

  14. Marra CA. "Basic concepts and evidence interpretation. Evidence-based medicine symposium (Session #2)". American Society of Health Systems Pharmacy 1998 Clinical Midyear Meeting. Las Vegas Convention Center, Las Vegas, Nevada, December 1998.

  15. Marra C. "A case-based approach to evidence-based medicine". American Society of Hospital Pharmacists Meeting, Las Vegas, Nevada, December 1998.

  16. Zed P. "Advances in the management of acute coronary syndromes". Canadian Society of Hospital Pharmacists (B.C. Branch) Annual General Meeting, Sheraton Wall Centre Hotel Vancouver, Vancouver, B.C., November 1998.

  17. Slavik R. "Update on AIDS-Related Infection". Canadian Society of Hospital Pharmacists (B.C. Branch) Annual General Meeting, Sheraton Wall Centre Hotel Vancouver, Vancouver, B.C., November 1998.

  18. Slavik R. "Aids-Related opportunistic infections: Review and what’s still true?". Canadian Society of Hospital Pharmacists (B.C. Branch) Annual General Meeting, Vancouver, B.C., November 1998.

  19. Shalansky K. "Management of Nausea and Cachexia". B.C. Nephrology Day, Vancouver, B.C., October 1998.

  20. Low A. "Considerations in the Generic Substitution of Medications". Crohn’s and Colitis Foundation of Canada and Northwestern Society of Intestinal Research - Medications and the Bowel Conference, Vancouver, B.C., October 1998.

  21. Low A. "The Transfer of Information via the PharmaNet Study - TIPS". College of Pharmacists of British Columbia - PharmaNet Users Group, Vancouver, B.C., October 1998.

  22. Warkentin D, Nevill, Gore J, Dossa A, Yip J, Toze CL, Barnett MI. "The relationship between the administration of cyclosporine/methotrexate prophylaxis and the development of acute graft versus host disease". The Royal College of Physicians and Surgeons of Canada, Toronto, Ontario, September 1998.

  23. Loewen P. "Seamless care: Partnerships between hospital & community pharmacists". Unipharm Inc. Continuing Education Conference, Richmond, B.C., September 1998.

  24. de Lemos J. "The Vancouver Interaction and Calmness Scale: development of a reliable, valid and responsive scale to measure quality of sedation in the critically ill". Royal College of Physicians and Surgeons of Canada 67th Annual Meeting, Toronto, Ontario, September 1998.

  25. Nicol R, Chase L. "Demystifying Vascular Access Devices". Canadian Society of Hospital Pharmacists, British Columbia Branch Annual General Meeting, Sheraton Wall Centre Hotel Vancouver, Vancouver, B.C., September 1998.

  26. de Lemos J. "Quality of Sedation in the ICU: From Coma to Combat". Canadian Society of Hospital Pharmacists, British Columbia Branch Annual General Meeting, Sheraton Wall Centre Hotel Vancouver, Vancouver, B.C., September 1998.

  27. Marra CA. "Cost-Effectiveness analysis of azithromycin and doxycycline for the treatment of Chlamydia infections in women" A Canadian perspective." 51st Annual Meeting of the Canadian Society of Obstetricians and Gynaecologists, Victoria Conference Centre, Victoria, B.C., June 1998.

  28. Marra F. "Pneumococcal immunization in HIV-positive patients". Clinical Rounds, B.C. Centre for Disease Control - Epidemiology Services, Vancouver, B.C., June 1998.

  29. Sunderji R, Shalansky K. "Outpatient Self-Management of Warfarin Therapy: A Pilot Study". Canadian College of Clinical Pharmacy, 6th Symposium, Delta Whistler Resort, Vancouver, B.C., June 1998.

  30. Shalansky K, Sunderji R. "A simple warfarin nomogram". CCCP conference, 6th Symposium, Delta Whistler Resort, Vancouver, B.C., June 1998.

  31. Partovi N. "Renal Transplant Immunosuppressants". British Columbia Transplant Society Continuing Education Event". Coyote Creek Golf Course, Surrey, B.C., July 1998.

  32. Partovi N. "Long term complications of Solid Organ Transplant: Hyperlipidemia and Osteoporosis". Transplant Conference, Holiday Inn, Vancouver, B.C., July 1998.

  33. Low A. "New Therapies for the Treatment of Parkinson’s Disease". Canadian Society of Hospital Pharmacists (B.C. Branch) Spring Drugs Update Renaissance Hotel, Vancouver, B.C., April 1998.

  34. Sunderji R. "New Thrombolytic Therapies". Canadian Society of Hospital Pharmacists (B.C. Branch) Spring Drugs Update Renaissance Hotel, Vancouver, B.C., April 1998.

  35. Low A. "New Parkinson’s Disease Therapy". Unipharm Professional Development Conference, Vancouver, B.C., April 1998.

  36. Low A. "Getting Pharmacists Involved in Clinics". Canadian Society of Hospital Pharmacists Annual Banff Seminar, Banff, Alberta, March 1998.

Internal Presentations

  1. Runikis A. "Drugs commonly used in Psychiatry". Clinical Clerks/MSI’s. Vancouver Hospital and Health Sciences Centre, UBC Site, (repeated at 10 sessions).

  2. Loewen P. "Postoperative nausea and vomiting in patients undergoing TRAM breast reconstruction surgery". UBC Hospital Anaesthesiologists, Vancouver Hospital and Health Sciences Centre, UBC Site, March 1999.

  3. Loewen P. "Antidepressants, anxiolytics and antipsychotics in acute care: a practical approach to their use and monitoring". Surgical and Family Practice/Palliative Care Nursing Staff, Vancouver Hospital and Health Sciences Centre, UBC Site, March 1999.

  4. Marra F. "A Case of Pseudomonas aeruginosa meningitis". Vancouver Hospital and Health Sciences Centre Infectious Diseases Intracity Rounds, Vancouver, B.C., February 1999.

  5. Warkentin D. "Adenoviral infections in recipients of stem cell transplantation". Bone Marrow Transplantation Seminar. Vancouver Hospital and Health Sciences Centre, VGH Site, February 1999.

  6. Sunderji R. "Outpatient self-management of warfarin therapy: A pilot study". Cardiology Academic Rounds. Vancouver Hospital and Health Sciences Centre, VGH Site, February 1999.

  7. Frighetto L. "Antiemetic prophylaxis for post-operative nausea and vomiting". Pharmacy staff, Vancouver Hospital and Health Sciences Centre, VGH Site, February 1999.

  8. Loewen P. "PONV in TRAM-flap breast reconstruction patients: An update on recent changes in practice". Surgical Patient Care Team, Vancouver Hospital and Health Sciences Centre, UBC Site, February 1999.

  9. Loewen P. "PONV in TRAM-flap breast reconstruction patients: A review of 140 cases at UBC Hospital". Surgical Patient Care Team, Vancouver Hospital and Health Sciences Centre, UBC Site, January 1999.

  10. Marra F. "Case studies in HIV/AIDS". Clinical Teaching Unit Grand Rounds, Vancouver Hospital and Health Sciences Centre, UBC Site, January 1999.

  11. Shalansky K. "Asthma patient teaching". CSU Pharmaceutical Sciences staff. Vancouver Hospital and Health Sciences Centre, VGH Site, January 1999.

  12. Slavik R. "Controversies in the treatment of MRSA infections". Infectious Diseases Intracity Rounds, Vancouver Hospital and Health Sciences Centre, Vancouver, B.C., December 1998.

  13. Zed PJ. "Advances in the management of acute coronary syndromes". CSU Pharmaceutical Sciences Rounds. Vancouver Hospital and Health Sciences Centre, VGH Site, December 1998.

  14. Shalansky K. "Asthma outcomes". CSU Pharmaceutical Sciences staff, Vancouver Hospital and Health Sciences Centre, VGH Site, November 1998, (repeated at 3 sessions).

  15. Low A. "Team enhancement - A follow-up". CSU Pharmaceutical Sciences staff, Vancouver Hospital and Health Sciences Centre, UBC Site, November 1998.

  16. Loewen P. "Appropriate use of antibiotics for preventing post-surgical infections". Operating Room nurses, Vancouver Hospital and Health Sciences Centre, UBC Site, November 1998.

  17. Warkentin D. "Cyclosporine levels and Acute Graft-versus-Host disease". Bone Marrow Transplantation Seminar. Vancouver Hospital and Health Sciences Centre, VGH Site, November 1998.

  18. Low A. "Special access program medications". Nursing and administration staff of Neurodegenerative Disorders Clinic, Vancouver Hospital and Health Sciences Centre, UBC Site, September 1998.

  19. Low A. "Team enhancement". CSU Pharmaceutical Sciences staff, Vancouver Hospital and Health Sciences Centre, UBC Site, September 1998.

  20. Warkentin D. "Facts about antineoplastic agents". Nursing Education Day. Vancouver Hospital and Health Sciences Centre, VGH Site, September 1998.

  21. Slavik R. "Treatment of endemic mycoses with antifungal agents". Infectious Diseases Intracity Rounds, Vancouver Hospital and Health Sciences Centre, Vancouver, B.C., September 1998.

  22. Slavik R. "Treatment of MRSA infections". Infectious Diseases Intracity Rounds, Vancouver Hospital and Health Sciences Centre, Vancouver, B.C., August 1998.

  23. Shalansky K. "Outpatient self-management of warfarin". Physicians. Vancouver Hospital and Health Sciences Centre, VGH Site, August 1998.

  24. Dossa A. "Side effects of medications used in Parkinson’s Disease and epilepsy". Vancouver Hospital and Health Sciences Centre, VGH Site, July 1998.

  25. Slavik R. "Magnesium for acute asthma: magnificent or myth?". CSU Pharmaceutical Sciences Rounds. Vancouver Hospital and Health Sciences Centre, VGH Site, July 1998.